The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.
 
Giampaolo Bianchini
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; MSD; NeoPharm; Novartis; Pfizer; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Lilly; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Pfizer; Roche
 
Matteo Dugo
No Relationships to Disclose
 
Balazs Gyorffy
No Relationships to Disclose
 
Giancarlo Bisagni
No Relationships to Disclose
 
Marco Colleoni
Research Funding - Roche (Inst)
 
Mauro Mansutti
Consulting or Advisory Role - Lilly; Novartis; Pfizer
Travel, Accommodations, Expenses - Roche
 
Claudio Zamagni
Honoraria - Istituto Gentili; Pierre Fabre; Takeda; Teva
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Eisai; Lilly; Novartis; Pfizer; PharmaMar; QuintilesIMS; Roche; Tesaro
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Medivation (Inst); Morphotek (Inst); Novartis (Inst); pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Celgene; Istituto Gentili; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche; Tesaro
 
Lucia Del Mastro
Honoraria - Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Travel, Accommodations, Expenses - Celgene; Pfizer; Roche
 
Stefania Zambelli
No Relationships to Disclose
 
Antonio Frassoldati
Consulting or Advisory Role - Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche
 
Luca Licata
No Relationships to Disclose
 
Barbara Galbardi
No Relationships to Disclose
 
Maria Olivia Biasi
No Relationships to Disclose
 
Lucia Viganò
No Relationships to Disclose
 
Alberta Locatelli
No Relationships to Disclose
 
Chanel Smart
No Relationships to Disclose
 
Giuseppe Viale
Honoraria - Daiichi Sankyo Europe GmbH; MSD Oncology; Pfizer
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Dako; Menarini; MSD Oncology; Novartis; Roche/Genentech
Speakers' Bureau - Roche/Genentech
Research Funding - Cepheid (Inst); Dako/Agilent Technologies (Inst); Roche/Genentech; Ventana Medical Systems (Inst)
Travel, Accommodations, Expenses - Roche
 
Pinuccia Valagussa
No Relationships to Disclose
 
Maurizio Callari
No Relationships to Disclose
 
Luca Gianni
Consulting or Advisory Role - ADC Therapeutics; AMGEN; AstraZeneca; BioMedical Insights; Celgene; Forty Seven; G1 Therapeutics; Genenta Science; Genentech; Genomic Health; Lilly; Menarini; Merck Sharp & Dohme; METIS Precision Medicine; Novartis; Odonate Therapeutics; Oncolytics; Onkaido Therapeutics; Pfizer; Revolution Medicines; Roche; Sandoz; Sanofi; Seagen; Synaffix; Synthon; Taiho Pharmaceutical; Zymeworks
Research Funding - Revolution Medicines (Inst); Zymeworks (Inst)
Patents, Royalties, Other Intellectual Property - Roche
Travel, Accommodations, Expenses - Celgene; Chugai Pharma; Pfizer; Roche